6 Results

People

  1. Rizvi
    Rizvi
  2. Hellmann
    Hellmann
  3. Arbour
    Arbour
  4. Rudin
    Rudin
  5. Sauter
    Sauter
  6. Cambridge
    Cambridge
  7. Chaft
    Chaft
  8. Fish
    Fish
  9. Halpenny
    Halpenny
  10. Kasler
    Kasler

Groups

  1. Department of Medicine (6)
  2. Solid Tumor Oncology Division (6)
  3. Thoracic Oncology (5)
  4. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (2)
  5. GSK Faculty (2)
  6. Advanced Practice Providers (1)
  7. Biostatistics Service (1)
  8. Body Imaging Service (1)
  9. Division of Subspecialty Medicine (1)
  10. Endocrinology (1)
  1. "pembrolizumab"
  2. "Hira Rizvi"
Formats
  1. Journal Article (4)
  2. Meeting Abstract (2)
Groups
  1. Department of Medicine (6)
  2. Solid Tumor Oncology Division (6)
  3. Thoracic Oncology (5)
  4. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (2)
  5. GSK Faculty (2)
  6. Advanced Practice Providers (1)

More Groups

People
  1. Hira Rizvi (6)
  2. Matthew Hellmann (5)
  3. Kathryn Arbour (3)
  4. Charles Rudin (2)
  5. Jennifer Sauter (2)
  6. Ai Ni (1)

More People

Years
  1. 2020 (1)
  2. 2019 (2)
  3. 2018 (2)
  4. 2017 (1)
Publications
  1. Annals of Oncology (3)
  2. Journal of Thoracic Oncology (2)
  3. Gynecologic Oncology Reports (1)
Publishers
  1. Oxford University Press (3)
  2. Elsevier Inc. (2)
  3. Elsevier B.V. (1)

Results (6)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50%
    Journal Article

    Gainor, J. F.; Rizvi, H.; Jimenez Aguilar, E.; Skoulidis, F.; Yeap, B. Y.; Naidoo, J.; Khosrowjerdi, S.; Mooradian, M.; Lydon, C.; Illei, P.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • STK11/LKB1 genomic alterations are associated with inferior clinical outcomes with chemo-immunotherapy in non-squamous NSCLC
    Meeting Abstract

    Skoulidis, F.; Arbour, K.; Hellmann, M.; Patil, P.; Marmarelis, M.; Owen, D.; Awad, M.; Murray, J.; Levy, B.; Hellyer, J.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression
    Journal Article

    Aguilar, E. J.; Ricciuti, B.; Gainor, J. F.; Kehl, K. L.; Kravets, S.; Dahlberg, S.; Nishino, M.; Sholl, L. M.; Adeni, A.; Subegdjo, S.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Outcomes in NSCLC patients treated with first-line pembrolizumab and a PD-L1 TPS of 50-74% vs 75-100% or 50-89% vs 90-100%
    Meeting Abstract

    Jomenez Alguilar, E.; Gainor, J.; Kravets, S.; Khosrowjerdi, S.; Lydon, C.; Adeni, A.; Subegdjo, S.; Rizvi, H.; Hellmann, M.; Awad, M.
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Next-generation sequencing based detection of germline and somatic alterations in a patient with four metachronous primary tumors
    Journal Article

    Martin, M.; Sabari, J. K.; Turashvili, G.; Halpenny, D. F.; Rizvi, H.; Shapnik, N.; Makker, V.
    Gynecologic Oncology Reports (2018)

    Fulltext@MSK | Save
  • Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer
    Journal Article

    Osorio, J. C.; Ni, A.; Chaft, J. E.; Pollina, R.; Kasler, M. K.; Stephens, D.; Rodriguez, C.; Cambridge, L.; Rizvi, H.; Wolchok, J. D.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save